Asset Details
Do you wish to reserve the book?
Ferroptosis and the eye: bridging the gap between cell death and vision preservation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ferroptosis and the eye: bridging the gap between cell death and vision preservation
Do you wish to request the book?
Ferroptosis and the eye: bridging the gap between cell death and vision preservation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ferroptosis and the eye: bridging the gap between cell death and vision preservation
2026
Overview
Ferroptosis, a recently discovered type of programmed cell death (PCD) distinguished by iron overload and lipid peroxidation, differs fundamentally from necrosis, apoptosis, and autophagy. Emerging evidence indicates that ferroptosis is deeply implicated in the disruption of the ocular microenvironment, wherein both structural and immune cells are significantly compromised. Rather than being an isolated cellular event, ferroptosis actively engages in a complex bidirectional crosstalk with the ocular immune system, driving neuroinflammation and tissue degeneration. In this review, we shift the paradigm from traditional disease-specific descriptions to the underlying microenvironmental interactions that dictate ocular health. Furthermore, we systematically evaluate the therapeutic potential of emerging interventions. Specifically, we highlight the latest breakthroughs in utilizing natural and dietary compounds as potent ferroptosis regulators. Crucially, we address current translational limitations by exploring advanced drug delivery systems, such as nanocarriers and hydrogels, designed to effectively overcome the blood-retinal barrier (BRB) and improve targeted efficacy. Ultimately, this review provides a comprehensive roadmap for advancing ferroptosis-targeted therapies from the laboratory to clinical ophthalmology.
